Therapeutic transformation for diabetic kidney disease.
Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Glucose; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; washington; spokane; PSHMC
Risks of kidney failure and heart failure are markedly reduced by inhibition of the sodium glucose cotransporter 2 (SGLT2) in patients with diabetic kidney disease. In a post hoc analysis of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial, drop-in SGLT2 inhibitor usage during the atrasentan enrichment period led to greater reduction in albuminuria compared with atrasentan alone. These data support the hypothesis of greater longer-term kidney protection by combination SGLT2 inhibition and endothelin A receptor antagonism that could be tested in future clinical trials.
Kidney & Diabetes
Tuttle, Katherine and Cherney, David Z I, "Therapeutic transformation for diabetic kidney disease." (2021). Articles, Abstracts, and Reports. 4296.